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Background: The interactions among cells or among cells and components of the extracellular matrix, is a crucial
pathophysiological process involving some molecules collectively known as adhesion molecules (CAMs).
Glycoprotein IIb / IIIa receptors are only restricted to blood platelets and they bind fibrinogen and adhesion
proteins such as fibronectin, vitronectin, von Willebrand factor to form cross bridges between adjacent platelets.
IIb/IIIa receptor antagonists are an object of intense research activity for target therapy worldwide during the last
decades. Three GPIIb/IIIa inhibitors, abciximab, tirofiban, and eptifibatide, have been approved for clinical use.
Profound thrombocytopenia is an uncommon but clinically important complication of glycoprotein IIb/IIIa
inhibitors.
Case presentation: This case report discusses a forty-four-year-old male patient with acute coronary syndrome
who underwent percutaneous coronary intervention and developed profound thrombocytopenia within 4 hours of
first administration of eptifibatide.
Conclusion: This report adds another case of eptifibatide-induced thrombocytopenia to the medical literature and
endorses the importance of platelet count monitoring after initiating therapy with this agent.
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The interactions among cells or among cells and compo-
nents of the extracellular matrix, is a crucial patho-
physiological process involving molecules collectively
known as adhesion molecules (CAMs). CAMs are ubi-
quitously expressed proteins with a key function in
physiological maintenance of tissue integrity and an emi-
nent role in various pathological processes such as
cardiovascular disorders, atherogenesis, atherosclerotic
plaque progression and regulation of the inflammatory
response. CAMs such as selectins, integrins, and im-
munoglobulin superfamily take part in interactions be-
tween leukocyte and vascular endothelium (leukocyte
rolling, arrest, firm adhesion, migration). Integrins
are a family of adhesion molecules performing a
major role in such multiple cellular functions including
carcinogenesis and metastatic process. The GP IIb/IIIa* Correspondence: kcharal@med.duth.gr
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reproduction in any medium, provided the orreceptors (fibrinogen or aggregation receptors), belong to
the family of integrins which are membrane bound
adhesion molecules and are made of two glycoprotein
sub-units (a and b). GP IIb/IIIa receptors are only
restricted to blood platelets and they bind fibrinogen
and adhesion proteins such as fibronectin, vitronectin and
von Willebrand factor to form cross bridges between
adjacent platelets. IIb/IIIa receptor antagonists are an object
of intense research activity for target therapy worldwide
during the last decades and they are frequently used during
percutaneous coronary intervention (angioplasty with or
without intracoronary stent placement) as well as treating
acute coronary syndromes, without percutaneous coronary
intervention. Three GPIIb/IIIa inhibitors, abciximab,
tirofiban, and eptifibatide, have been approved for clinical
use. All are given by intravenous administration, usually
for 12 to 18 h after the patient undergoes angioplasty
[1-4]. This case report discusses forty-four-year-old male
patient who developed profound thrombocytopenia within
4 hours of first administration of eptifibatide.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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A 44-year-old Caucasian male with no previous history
of cardiovascular disease presented to the emergency
department of the hospital with a two-hour history
of retrosternal chest pain radiating to the left arm and
mandible. He denied any previous history of blood
dyscrasia or thrombocytopenia. He had no history of
cardiac disease, drug abuse, and he mentioned two car-
diovascular risk factors (tobacco abuse and hyperlipid-
emia). Additionally, he denied any history of a previous
hospitalization where he may have received heparin or
eptifibatide. His electrocardiogram (ECG) showed sinus
rhythm with diffuse ST elevation of the II, III, aVF, V3 to
V6 leads and reciprocal changes in I, aVL (Figure 1)
without any hemodynamic compromise (blood pressure
120/85 mmHg). His early management included treat-
ment with intravenous unfractionated heparin (5000 unit
bolus) followed by an infusion of 18 units/kg/hr, aspirin
325 mg, clopidogrel 600 mg, iv nitrates at a constant in-
fusion, b-blockers (metoprolol 50 mg), intravenous mor-
phine (4 mg), and oxygen 2 l/min. The patient had a
white blood cell count of 11.000/mm3, a hemoglobin
level of 14.0 g/dL, and a platelet count of 220,000/mm3.
Values of prothrombin time (PT) and activated partial
thromboplastin time (aPTT) were within normal limits.
Due to the fact that the hospital was unable to perform
percutaneous coronary intervention (PCI) or transfer the
patient to a tertiary institute at a time less than 120 mi-
nute to PCI (door to needle), fibrinolytic therapy was de-
cided upon and performed (tenecteplase 50 mg iv bolus)
in the absence of any contraindications (absolute or rela-
tive). The symptoms 60 min after the medical revascu-
larization did not reside, the ST-elevation remained
unchanged, and reperfusion arrhythmias were not no-
ticed. Taking into consideration all the above reasons,Figure 1 Patient’s electrocardiogram on admission.the patient was immediately transferred to the cardiac
catheterization laboratory of our clinic for a rescue
PCI. Coronary angiography showed that the left main
coronary artery (LMCA) was a wide atheromatic vessel
without critical stenoses, the left anterior descending
coronary (LAD) artery was a relatively large vessel, with
sparse atheromatic plaques and revealed a longitudinal
critical stenosis of 70% immediately after the origin of a
large diagonal branch (Figure 2). The left circumflex ar-
tery (LCx) had a 70% stenosis at the level of the bifur-
cation with the first obtuse marginal branch (Figure 2).
The right coronary artery was totally occluded with a re-
sidual thrombus (Figure 3), with a Thrombolysis in Myo-
cardial Infarction (TIMI) flow of 0. Protherapy (class IIa
indication) with eptifibatide was decided due to the in-
creased thrombus load of the right coronary artery
(RCA) for at least 1 hour as an adjuvant measure before
proceeding to the percutaneous transluminal coronary
angioplasty (PTCA). The patient received an intravenous
double bolus of 180 μg/kg of eptifibatide (10 minutes
apart), followed by a 2 μg/kg/min infusion.
A 3.0×24 mm PROMUS™ Element™ stent was deployed
in the LAD with a very satisfying angiographic result
(TIMI 3), the lesion of the LCx was also managed with
the use of 3.0×24 mm PROMUS™ Element™ stent achiev-
ing an excellent result (TIMI 3). At the right coronary
artery, thrombus extraction catheter (Thrombuster II)
was used to remove the discrete, intraluminal filling de-
fect that was noted within the infarct-related artery.
Multiple passages were carried out in order to restore
the flow and an important amount of thrombus load
was aspirated using a 6-Fr Thrombuster II. The patient
then underwent successful stenting of the right coronary
artery (Figure 4) with the deployment of a 3.0×32 mm
PROMUS™ Element™ distally and 3.0×20 mm PROMUS™
Figure 2 Coronary angiography of the left coronary artery after admission to the hospital. Arrows indicate longitudinal critical stenosis of
70% immediately after the origin of a large diagonal branch and a 70% stenosis at the level of the bifurcation with the first obtuse marginal
branch of the left circumflex artery.
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RCA, the patient became pain-free and had resolution of
ST segment elevation. He was transferred in a stable
condition to the coronary care unit. Post-percutaneous
coronary intervention medications included aspirin
100 mg po daily, ramipril 5 mg po daily, metoprolol suc-
cinate 50 mg per os daily, clopidogrel 75 mg po daily,
rosuvastastin 20 mg po daily, and the eptifibatide infu-
sion was to be continued for 18 hours.
Approximately four hours post-percutaneous coronary
intervention and eptifibatide initiation, the patient devel-
oped profound thrombocytopenia, with his platelet count
dropping by over 90% from baseline to 15,000/mm3 while
the hemoglobin level remained stable (Figure 5). A periph-
eral blood smear showed no signs of platelet clumping,
ruling out pseudothrombocytopenia and no evidenceFigure 3 The right coronary artery was totally occluded (red arrow poof microangiopathic hemolytic anemia. All antiplatelet
products including heparin, eptifibatide as well as dual an-
tiplatelet therapy (DAPT) was discontinued for 48 hours
due to the profound thrombocytopenia 15,000/mm3, out-
weighing the risk of an early stent thrombosis with the
risk of a fatal bleeding event such as an intercranial
hemorrhage that would suspend the dual antiplatelet ther-
apy for an indefinitive time period. Moreover patient
related factors for acute stent thrombosis (<24 h of im-
plantation) such as renal failure, diabetes mellitus and low
ejection fraction were not present to our patient [5]. The
patient was thereafter consulted to our hematology de-
partment. The patient’s platelet level reached its nadir
(5,000/mm3) approximately 6 hours post-eptifibatide initi-
ation. A heparin-induced thrombocytopenia (HIT) [6,7]
platelet factor 4 antibody test was negative [8,9]. Theinting to the lesion) with a residual thrombus.
Figure 4 Successful stenting of the right coronary artery.
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Platelets (5 packs, total) were transfused in the next
24 hours. After the transfusions, the platelet count in-
creased from 5,000/mm3 to 60,000/mm3. Subsequently,
the patient’s platelet count continued to rise (80,000/mm3)
48 hours after the eptifibatide exposure, which enabled
us to restart both aspirin and clopidogrel. The patient
showed no signs of active bleeding, bruises, ecchymosis,
or petechiae during the hospitalization and was discharged
on day five having a platelet count of 182,000/mm3, free
of symptoms.
Conclusions
While eptifibatide presents significantly improved out-
comes in patients undergoing percutaneous coronary
intervention and among those presenting with an acuteFigure 5 Chart presenting the development of profound thrombocyt
baseline to 15,000/mm3 during the first hours.coronary syndrome, a small number of patients given
eptifibatide develop acute profound thrombocytopenia
(20.000 cells/mm3) within hours of receiving the drug
that can increase the risk of serious bleeding with some-
times deleterious effects. The disorder appears to occur
less frequently in clinical trials of eptifibatide, the hepta-
peptide small molecule GPIIb-IIIa inhibitor. In the PUR-
SUIT trial (Platelet Glycoprotein IIb/IIIa in Unstable
Angina: Receptor Suppression Using Integrilin Therapy),
which involved patients with non-ST-elevation acute
coronary syndrome, acute profound thrombocytopenia
occurred in five (0.1%) of 4614 patients treated with
eptifibatide and in two of 4603 patients who received
placebo [10]. In the ESPRIT trial (Enhanced Suppression
of the Platelet IIb/IIIa Receptor with Integrilin Therapy)
of non emergent coronary angioplasty with stenting,openia, with a platelet count dropping by over 90% from
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(0.2%) of 1040 patients treated with eptifibatide and
in none of the 1024 placebo-treated patients [11]. In
the Integrilin to Minimize Platelet Aggregation and
Coronary Thrombosis (IMPACT-II) the incidence of
thrombocytopenia approximates the 2.8% [12]. Pro-
found thrombocytopenia is an uncommon but clinic-
ally important complication of glycoprotein IIb/IIIa
inhibitors [13-15].
Drug induced profound thrombocytopenia [16], a pre-
dictor of adverse outcome in patients with acute coron-
ary syndromes, is defined as a decrease in platelet count
to below 20,000/mm3 within 24 hours of exposure to the
drug and may be associated with the administration of
eptifibatide, a glycoprotein antagonist. While the usage
of GP IIb/IIIa inhibitors sets an important clinical bene-
fit in the management of ACS, the reporting incidence
of acute profound thrombocytopenia induced by eptifi-
batide is 0.1% to 1% and usually occurs within the first
24 hours. Several pathophysiological mechanisms have
been implicated in the explanation of GP IIb/IIIa inhib-
itors induced acute profound thrombocytopenia. Accu-
mulating evidence has indicated that pre-existing drug
dependent antibodies to platelet surfaces are present in
patients and that the glycoprotein inhibitors may in-
duce a change in the conformation in the GP IIb/IIIa
receptors on the platelet surface, leading to the expression
of neoepitopes which are recognized by pre-existing
serum antibodies [17,18]. Another possible mechanism
would be the formation of a receptor-antagonist complex
by the recognized neoepitopes. In our patient, the phys-
iological platelet count and all other hematological param-
eters (PT, aPTT, red blood cells, white blood cells) ruled
out bone marrow dysfunction, non-immune and im-
mune thrombocytopenia as a cause of thrombocytopenia.
Pseudothrombocytopenia was ruled out by manual exam-
ination of blood film [19]. There is no evidence in the
literature which suggests that the use of tenecteplase is
responsible for provoking thrombocytopenia. Not even
in the drug monography summary of product character-
istics (spc) is mentioned the likelihood of emerging
thrombocytopenia after the use of this drug. Additionally,
serotonin release assay (HIT panel) came back negative.
The fact that the patient continued to be on clopidogrel
without recurrence of thrombocytopenia after the nor-
malization of platelet count ruled out clopidogrel as a
cause of thrombocytopenia. No history of prior eptifiba-
tide exposure was present and the Naranjo scale score
[20] was 5, indicating a possible relationship between the
adverse effect and therapy in this patient. There is an algo-
rithm that has been proposed for the early evaluation and
management of this drug related thrombocytopenia. In all
patients that receive GP IIb/IIIa inhibitors a complete
blood count should be obtained prior to treatment, within2 hours following the intravenous bolus, in a daily basis
after the intervention and again prior to the patient’s dis-
charge [21,22].
This report adds another case of eptifibatide induced
thrombocytopenia to the medical literature and endorses
the importance of platelet count monitoring after initiat-
ing therapy with this agent.
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